Cachexia
A severe wasting syndrome characterized by loss of muscle and fat tissue, often associated with cancer, HIV, or chronic disease. Distinct from sarcopenia in its metabolic and inflammatory drivers.
Frequently Asked Questions
What is Cachexia?
A severe wasting syndrome characterized by loss of muscle and fat tissue, often associated with cancer, HIV, or chronic disease. Distinct from sarcopenia in its metabolic and inflammatory drivers.
Why is Cachexia important in peptide research?
Understanding cachexia is important because it represents a health condition where peptide interventions are being actively researched. Knowledge of the underlying pathology helps inform peptide selection and protocol design.
Related Terms
Sarcopenia
Age-related loss of skeletal muscle mass and strength that typically begins after age 30, accelerating after 60. Peptides targeting GH secretion (ipamorelin, CJC-1295) and myostatin inhibition (follistatin) are studied as interventions.
InflammationThe body’s immune response to injury, infection, or irritation. Acute inflammation is protective; chronic inflammation drives disease. Many peptides (BPC-157, KPV, LL-37, Thymosin Alpha-1) modulate inflammatory pathways.